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ABSTRACT 
The aim of the work is to design Gastroretentive tablets of Ondansetron HCl for gastric retention by using 32 factorial designs. 
Floating tablets of Ondansetron HCl were prepared by direct compression method using polymers, sodium alginate and excipient. 
Gastroretentive tablets of Ondansetron HCl were successfully prepared by effervescent technique using different gel forming 
polymers- HPMC K200M, and sodium alginate. Formulation was optimized by design expert software. Floating tablets were 
evaluated for floating time, floating lag time, drug content, raft measurement and in vitro dissolution profile. The lag time is between 
17-22 sec and floating time of the formulations for 12 hrs. The best fit model is Korsemeyer Peppas Model. From the study it is 
proof that the sustain release by floating tablets of Ondansetron HCl can be develop. Optimized batch selected was A3, The prepared 
gastroretentive test formulation was found to exhibit satisfactory physico-chemical characteristics at the end of 3 months, during the 
stability studies. The optimized formulation A3 was found to be stable at 400C/ 75% RH. 
Keywords: Gastric retention time, Ondansetron HCl, HPMC, sodium alginate, measurement of raft, Factorial design, stability 
studies. 
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INTRODUCTION 
Oral delivery of drug is the most preferred route of drug 
delivery due to ease of administration, patient 
compliance & flexibility in formulation. Conventional 
oral dosage forms achieve as well as maintain drug 
concentration within therapeutically effective range 
needed for treatment only when taken several times a 
day.It is having low bulk density that have sufficiently 
buoyancy to float over the gastric contents and remain 
buoyant in the Gastric juice of stomach without affecting 
the gastric emptying rate for a prolonged period of time
1
. 
Bioavailability
1,2
. 
Raft forming system: 
This system focus more for delivery of antacid and 
delivery of drugs used to treat gastrointestinal infection 
and disorders. The basic mechanism involves formation 
of viscous cohesive gel when the system comes in 
contact with gastric fluid. In this each portion of liquid 
swells and forms a continuous layer of gel known as raft. 
The raft floats because of buoyancy created by 
formation of CO2. This raft acts as a physical barrier to 
prevent the reflex of gastric content into the esophagus. 
This raft forming system contains a gel forming agent 
and alkaline bicarbonates or carbonates which is 
responsible for making the system less dense than the 
gastric fluid and to float on the gastric fluid
3,4
.  
Effect of sodium bicarbonate on the drug release 
from raft forming system: 
 Sodium bicarbonate is used as a gas generating agent. 
Gas generating agent sodium bicarbonate interacts with 
the gastric acid and generates carbon dioxide which gets 
entrapped within the swellable matrix. Carbonate or 
bicarbonate may be present in the amount ranges from 
Shaikh et al                                                                                                        Journal of Drug Delivery & Therapeutics. 2018; 8(4):185-195           
ISSN: 2250-1177                                                                             [186]                                                                             CODEN (USA): JDDTAO 
5% to 50% and preferably from about 10% to 30% by 
weight of composition. Increasing the concentration of 
bicarbonate decreases the floating lag time because of 
faster and higher carbon dioxide generation. At higher 
concentration of effervescent agent, coating of the tablet 
becomes less stable. This is because of increase in the 
internal pressure and there by rupturing the polymer 
coating which ultimately results in sudden increase in 
drug release
5,6,7
.  
Therefore the present study is planned to formulate & 
evaluate floating tablet of Ondansetron hydrochloride 
using HPMC K200M &HPMC K4M polymers, sodium 
alginate & excipients. Floating drug delivery systems 
have an efficient means of enhancing the bioavailability 
and controlled delivery of many drugs. Dosage forms 
with a prolonged GRT will bring about new and 
important therapeutic options. The data obtained thus 
suggests that floating delivery system of Ondansetron 
hydrochloride can be successfully designed to give 
controlled drug delivery and improved oral 
bioavailability. 
MATERIALS AND METHODS 
Ondansetron HCl, HPMC K-200 M, HPMC K-4 M, 
Sodium Bicarbonate, Citric Acid, Magnesium Stearate, 
Talc, Lactose , Sodium Alginate And Avicle-101. 
For study purpose, 9 formulations with different 
excipient were prepared as shown in table 1. Mixture 
passed through the sieve for purpose of uniformity of 
particle and remaining particle again triturated and 
mixed. Floating tablet was prepared by dry compression 
method. The tablet was compressed using (9mm punch) 
set in a compression machine. 
 
Table 1: Optimization batches design 
 
Ingredients 
Formulation batch code  
A1 A2 A3 A4 A5 A6 A7 A8 A9 
 Ondansetron Hcl 20 20 20 20 20 20 20 20 20 
 HPMC K-200 M 30 30 30 40 40 40 50 50 50 
 HPMC K-4 M 20 30 40 20 30 40 20 30 40 
 Sodium alginate 30 30 30 30 30 30 30 30 30 
 Sodium bicarbonate 45 45 45 45 45 45 45 45 45 
 Citric acid 15 15 15 15 15 15 15 15 15 
   Talc  05 05 05 05 05 05 05 05 05 
 Magnesium  stearate 05 05 05 05 05 05 05 05 05 
  Lactose  Q.S. 80 70 60 70 60 50 60 50 30 
 Total 250 250 250 250 250 250 250 250 250 
 
Evaluation Parameters: 
Pre-compression evaluation parameters: 
Angle of repose, bulk density, tapped density,carr’s 
index and hausner’s ratio were evaluated to determine 
the flow property of the prepared powder mixture. 
Post- compression evaluation parameters: 
Thickness:  
Thickness was measured using a vernier caliper. Five 
tablets of the formulation were picked randomly and 
thickness was measured individually.  
Hardness:  
Hardness was measured using Monsanto hardness tester. 
The hardness expressed in kg/cm2. For each batch three 
tablets were tested.  
 Friability:  
Twenty tablets were weighed and placed in the Roche 
friabilator and apparatus was rotated at 25 rpm for 4 
minutes. After revolutions, the tablets were deducted 
and weighed again. The percentage friability was 
measured using formula,  
% F = {1-(Wt. /W)} ×100  
Where, % F = Friability in percentage  
W = Initial weight of tablets  
Wt. = Weight of tablets after revolution  
 Weight variation:  
Twenty tablets were randomly selected from each batch 
and individually weighed. The average weight and 
standard deviation of 20 tablets was calculated. The 
batch passes the test for weight variation test if not more 
than two of the individual tablet weight deviate from the 
average weight. 
Drug Content Uniformity:  
Ten tablets for each batch was taken and triturated. 
Powder equivalent to 20 mg of drug was weighed and 
was transferred to breaker and 0.1N HCl was added and 
it was then shaken for 5 min and finally 0.1N HCl was 
added to make the volume up to 100 ml and solution 
was then sonicated for 15 min and filtered through 
Whatman filter paper. Finally, a solution was diluted 
suitably and the absorbance of the resultant solution was 
measured to determine the drug content 
spectrophotometrically at 310 nm using UV/Visible 
spectrophotometer Shimadzu 1800 against 0.1N HCl 
blank. 
In-vitro Buoyancy Studies: 
The in-vitro buoyancy was determined by floating lag 
time. The time required for the tablet to rise to the 
surface and float was determined as floating lag time. In 
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this the tablets were placed in 100 ml beaker containing 
0.1 N HCL. 
 Swelling index study: 
For each formulation batch, one tablet was weighed and 
placed in a beaker containing 200 ml of buffer media. 
After each interval the tablet was removed from beaker 
and weighed again up to 12 h. The swelling index was 
calculated using following formula.  
Swelling index (S.I) = {(wt-wo) /WO} ×100 
Where, S.I. = Swelling index 
Wt. = Weight of tablet at time t 
WO = Weight of tablet before placing in the Beaker. 
Raft strength measurement 
1. A tablet powder equivalent to unit dose was 
transferred to 150 ml of 0.1 N HCl and maintained 
at 37°C in a 250 ml glass beaker.  
2. Each raft was allowed to form around an L-shaped 
wire probe (Height 9 cm and wide at bottom surface 
2 cm) held upright in the beaker throughout the 
whole period (30 min) of raft development.   
3. Raft strength was estimated using the modified 
balance method.  
4. Water was added drop wise to the left sided beaker 
and the weight of water required to break the raft 
was recorded. 
Raft weight and raft volume measurement 
1. Raft volume and raft weight Rafts were calculated 
by taking unit dose for 30 min in glass   beakers of 
150 ml 0.1 N HCl but without the inclusion of a 
wire probe.  
2. Each beaker used for raft formation was reweighed 
(W1).  
3. Note the volume of beaker before formation of raft. 
(M1).  
4. The position to which the top of each raft reached 
was marked on the outside of the beaker.  
5. The total weight of the beaker and contents was 
obtained after raft development (W2).  
6. The weight of each raft was then calculated from 
the formula: 
Raft weight = Total weight of the beaker and contents 
was obtained after raft development (W2) – Pre-
weighed beaker used for raft formation (W1).  
1. The raft was then removed from the beaker by 
carefully decanting off the liquid and tipping the 
raft into a pre-tarred plastic weighing petri plate. 
2. This was left to stand for 30 s, excess subnatant 
liquid was drained off and the raft was weighed 
(W3).  
3. Remaining liquid was removed from the inside of 
the beaker with a paper towel and it was then 
refilled with water to the marked position (M2). 
4. Finally beaker was weighed (W4).  
5. The volume of each raft was then calculated from 
the formula:   
Raft volume = Final volume of 0.1 N HCl after 
formation of raft (M2) –Initial volume of 0.1 N HCl 
before formation of raft (M1)Where raft volume is 
measured in ml. and all weights are measured in gm.  
The formula assumes that the density of the subnatant 
liquid is the same as that of water. 
Acid neutralization capacity 
1) A tablet powder equivalent to unit dose was 
transferred to a 250 ml beaker; 50 ml of water was 
added to it and was mixed on a magnetic stirrer for 
1 min.  
2) A 30-ml volume of 1.0 N HCl was added with 
continued stirring on the magnetic stirrer for 10 min 
after addition of the acid.  
3) Stirring was discontinued briefly and the gum base 
was removed using a long needle without delay.  
4) The needle was promptly rinsed with 20 ml of 
water, and the washing was collected in the beaker; 
stirring was resumed for 5 min. 
5) Titration was begun immediately. Excess HCl was 
titrated against 0.5 N sodium hydroxide to attain a 
stable pH of 3.5.   
6) The number of mEq of acid consumed by the tablet 
tested was calculated by the following formula:  
 
Total mEq = (30×N HCL) – (V NaOH x N NaOH)  
Where, N HCI = Normality of HCl; V NaOH = Volume 
of NaOH required; and N NaOH = Normality of NaOH. 
In Vitro Dissolution Studies: 
In-vitro drug release studies of the prepared floating 
tablets were conducted for a period of 12 hrs. Using 
USP type II apparatus (paddle) at 37± 0.5°C and at 50 
rpm speed at pH 1.2. After withdrawing, the samples 
were analyzed by a UV spectrophotometer at 310 nm. 
Stability studies of optimized formulation: 
Procedure:  
In the present study, stability studies were carried out at 
room temperature 40 ± 20
0
C and 75 ± 5% RH for a 
specific time period up to 3 Months for selected 
formulations. For stability study, the tablets were sealed 
in aluminium packaging coated inside with 
polyethylene.
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RESULTS AND DISSCUSSION 
FT-IR Study of Drug 
 
Figure 1: FT-IR spectra of Ondansetron HCl. 
Table 2: Interpretation of FT-IR spectra of Ondansetron HCl (pure drug) 
Sr. No Functional group Characteristic peaks cm
-1
 Observed peaks cm
-1
 
1 N-H 3000-3700 3502.85 
2 C-H 2700-3300 2810.38 
3 C=O 1600-1900 1637.62 
4 C=N 1600-1900 1612.54 
5 C-H 1300-1500 1338.64 
6 C-C 800-1200 910.43 
 
FTIR Spectra of Ondansetron HCl (Pure Drug). 
The IR spectrum of pure drug was found to be similar to the reference standard IR Spectrum of Ondansetron HCl given 
in Indian pharmacopoeia. The IR Spectrum value of Odansetron HCl shown in table 2. 
Drug - Excipient Compatibility Studies 
 
Figure 2: FT-IR spectra of Drug + HPMC K200 M 
 
Figure 3: FT-IR spectra of Drug + HPMC K4 M 
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Figure 4: FT-IR spectra of Drug + HPMC K200 M+HPMC K4M 
Drug - Excipient Compatibility Studies 
Compatibility studies of pure drug Ondansetron HCl 
with polymers were carried out prior to the preparation 
of tablets. IR spectra of pure drug Ondansetron HCl and 
that of with polymerswere obtained, which are shown in 
figure No.1 to Figure No.4 All the characteristic peaks 
of Ondansetron HCl were present in spectra thus 
indicating compatibility between drugs. It shows that 
there was no significant change in the chemical integrity 
of the drug. 
DSC OF Ondansetron HCl: differential scanning 
calorimetric (DSC) 
 
 
Figure 5: Differential Scanning Calorimetry Ondansetron HCL 
 
Figure 6: DSC of Ondansetron HCl with Excipients 
Studies were carried out using DSC 60, having TA60 
software, shimadzu, and Japan. Accurately weight 
sample were placed on aluminum plate, sealed with 
aluminum lid and heated at a constant rate 5 
0
C/min over 
a temperature rang 0 to 250 
0
C. Ondansetron HCl 
showed in figure 5 & 6. 
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Table 3: Pre Compression Parameter optimized batches: 
Batch 
No. 
Angle 0f 
Repose (θ) 
Bulk Density 
(gm./ml)
 
Tapped Density 
(gm./ml) 
Hausner's Ratio Carr's Index 
(%) 
A1 29.68±0.46 0.728±0.02 0.823±0.005 1.12±0.02 11.21±0.02 
A2 30.96±0.01 0.684±0.01 0.782±0.001 1.14±0.02 12.53±0.02 
A3 27.92±0.02 0.632±0.002 0.715±0.001 1.13±0.02 11.60±0.02 
A4 27.47±0.07 0.589±0.001 0.647±0.001 1.09±0.04 8.96±0.02 
A5 26.56±0.02 0.561±0.002 0.624±0.002 1.11±0.01 10.09±0.02 
A6 23.74±0.02 0.543±0.001 0.602±0.001 1.10±0.02 9.80±0.01 
A7 25.64±0.01 0.518±0.001 0.582±0.001 1.12±0.02 10.99±0.00 
A8 26.10±0.02 0.482±0.001 0.562±0.001 1.17±0.02 14.53±0.02 
A9 26.11±0.01 0.561±0.01 0.637±0.001 1.11±0.01 10.09±0.01 
 
The prepared gastroretentive drug delivery system for 
raft forming tablets were characterized for angle of 
repose, bulk density, tapped density, carr’s index and 
hausner’s ratio which are shown in table. Angle of 
repose of all batches was within 23.74° – 30.96°, carr’s 
index of all batches was within 8.96 – 14.53 and 
hausner’s ratio of all batches was found within 1.09– 
1.17 which indicate good flow property of powder. 
 
Table 4: Post-Compression Parameters of optimized batches: 
Formulations Weight Variation 
(mg) 
Hardness 
(kg/cm
2
) 
Thickness 
(mm) 
Friability 
(%) 
(%)Drug 
Content 
A1 250±0.2 5.9 kg/cm
2
 4.5 0.49±0.11 99.31 
A2 251±0.1 5.8 kg/cm
2
 3.5 0.42±0.01 98.86 
A3 249±0.0 5.9 kg/cm
2
 4.5 0.41±0.00 98.64 
A4 251±0.3 6.0 kg/cm
2
 3.3 0.50±0.09 98.02 
A5 249±0.4 6.2 kg/cm
2
 4.2 0.48±0.07 97.53 
A6 249±0.0 6.5 kg/cm
2
 4.5 0.43±0.02 97.75 
A7 250±0.4 6.3 kg/cm
2
 4.5 0.41±0.00 98.02 
A8 250±0.2 6.4 kg/cm
2
 4.4 0.45±0.04 98.41 
A9 249±0.07 5.2 kg/cm
2
 3.5 0.51±0.02 99.08 
 
Hardness test  
The measured hardness of tablets of each batch ranged 
between 5.2 to 6.5kg / cm2 This ensures good handling 
characteristics of all batches. 
Thickness 
The measured thickness of tablets of each batch ranged 
between 3.3 to 4.5 this ensures good handling 
characteristics of all batches. 
Friability test   
The values of friability test of tablets of each batch 
ranged between 0.41-0.51% The % friability was less 
than 1% in all the formulations ensuring that the tablets 
were mechanically stable.  
Weight variation test 
The percentage weight variations for tablets of each 
batch ranged between 249-251mg all the tablets passed 
weight variation test as the % weight variation was 
within the Pharmacopoeial limits of ±5% of the weight. 
The weights of all the tablets were found to be uniform 
with low standard deviation values.  
Drug content uniformity  
The percentage of drug content was found to be between 
97.53% and 99.31% of It Ondansetron hydrochloride, 
which was within acceptable limits. The results of drug 
content uniformity in each batch. 
Table 5: In-vitro buoyancy study of optimized batches 
Formulation 
Codes 
Floating Lag Time 
(Sec) 
Total FLT 
Hours 
A1 17 ± 0.1 >12 
A2 17 ± 0.1 >12 
A3 30 ± 0.2 >12 
A4 32 ± 0.3 >12 
A5 20 ± 0.1 >12 
A6 18 ± 0.1 >12 
A7 20 ± 0.2 >12 
A8 19 ± 0.1 >12 
A9 22 ± 0.4 >12 
Buoyancy study 
On immersion in 0.1N HCl solution pH (1.2) at 37oC, 
the tablets floated, and remained buoyant without 
disintegration. The results of buoyancy study and 
showed buoyancy character of prepared tablet of 
formulation. Formulation shows floating lag time as 
17sec. which was less compared to other formulations. 
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Table 6: Data for Raft Strength and Acid Neutralizing Capacity: 
Batch no Raft Strength (gm) Acid Neutralizing Capacity (mEq)
* 
A1 0.58±0.1 6±0.2 
A2 0.65±0.2 7±0.1 
A3 0.59±0.1 6±0.1 
A4 0.57±0.1 6±0.0 
A5 0.59±0.0 6.5±0.0 
A6 0.66±0.2 7.2±0.1 
A7 0.66±0.3 6.6±0.1 
A8 0.68±0.1 7±0.1 
A9 0.73±0.2 7.1±0.1 
 
Raft strength, Acid Neutralizing Capacity 
All the parameters are evaluated using 0.1 N HCl in 
specific procedure taking 10 tablets for evaluation of 
both the evaluation parameter 
According to data of both specific evaluation parameter 
of the raft forming formulation, A9 batch was having 
maximum raft strength, &Acid Neutralizing Capacity 
range between”(6-7.2).So it was selected as an ideal 
formulation as raft formation tablet.  
% Swelling Index of Optimized batches in graphical 
presentation:
 
 
Figure 7: % swelling index of optimized batches 
 
Swelling Index: 
Swelling index of all batches i.e. A1 to A9 is maximum 
% of wt. 95.5%, 105.01%, 137.65%, 126.53%, 138.30%, 
158.13%, 145.90%, 163.26% and 108.41 respectively. 
Show in figure No.7 
 
 
Figure 8: %Drug Release in Graphical Presentation: 
(A1 to A9) 
In Vitro dissolution studies: 
The release rate of Ondansetron hydrochloride from 
floating tablets was determined using The United States 
Pharmacopoeia (USP) XXIV dissolution testing 
apparatus II (paddle method). The dissolution test was 
performed using 900 ml of 0.1 N HCl, at 37 ± 0.5°C and 
50 rpm A sample (1 ml) of the solution was withdrawn 
from the dissolution apparatus, and volume equivalent to 
the amount of sample withdrawn was replaced with 
fresh dissolution medium. The samples were visualized 
on UV at 310nm after appropriate dilutions. Absorbance 
data obtained was substituted in the equation of standard 
curve and values were calculated for total cumulative 
amount of drug released. All the nine formulation of 
prepared floating tablets of Ondansetron hydrochloride 
were subjected to in-vitro release studies these studies 
were carried out using dissolution apparatus, 0.1N HCL 
(pH 1.2) 
The drug release batch A1, A2, A3, A4, A5, A6, A7, A8 
and A9 were found 94.30%, 93.15%, 97.48%, 88.87%, 
95.44%, 86.96%, 82.94%, and 80.22%, and 78.63% 
respectively.
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Data analysis: 
Table 7: In-vitro Drug release data Analysis 
Batch Zero order First order Higuchi Korsmeyer-
peppas 
Hixson-Crowell 
A1 R Slope R Slope R Slope R Slope R Slope 
0.9512 8.4131 0.8466 0.0860 0.9612 39.002 0.9873 1.0206 0.7144 0.5168 
N 
0.9307  
 
Data Analysis: 
The in-vitro release data was subjected to goodness of fit 
test by linear regression analysis according to zero order, 
first order kinetic equations, higuchi equation, 
korsmeyer-peppas and Hixson-Crowell models to 
ascertain the mechanism of drug release. The results of 
linear regression analysis of data including regression 
coefficient are summarized in Table 7. 
When the regression coefficient ‘r’ value of Zero order 
and korsmeyer-peppas plots were compared, it was 
observed that the ‘r’ values of Zero order was found to 
be 0.9512 whereas the ‘r’ values of korsmeyer-peppas 
plot was found to be 0.9873 indicating drug release from 
optimized formulation was found to follow Korsmeyer-
peppas kinetics.  
The in-vitro dissolution data was fitted to Korsmeyer-
equation, values of exponent ‘n’ was found to be 0.9307 
indicating that the drug release is by Anomalous 
transport mechanism. 
  
 
 
 
 
 
Figure 9: Release Profile of Ondansetron HCl 
 
Table 8: Result of ANOVA 
Response model Sum of 
square 
Degree of 
freedom 
Mean 
square 
F value P value R square Model 
significant/            
Not-Significant 
%drug release 280.57 12 
  
55.76 63.28 <0.0001 0.9784 Significant 
Raft strength 0.0293 12 
  
0.0049 7.34 0.0105 0.8399 Significant 
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Figure 10: A response surface plot showing effect of concentration of independent variables on the Raft 
strength. 
 
Figure 11: A counter plot showing relationship between various levels of independent variables to gain fixed 
value of Raft strength. 
 
Figure 12: A response surface plot showing effect of concentration of independent variables on the % drug 
release 
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Figure 13: A counter plot of showing relationship between various levels of independent variables to gain fixed 
value of % drug release. 
Stability Study 
Table 9: Stability study of optimized formulation batch  
Condition Time 
(month) 
Hardness 
(Kg/cm
2
) 
Friability 
(%) 
Drug 
content (%) 
Floating lag 
time (Sec) 
% Drug 
release 
Accelerated temperature 
40
0
C and 75% RH 
3 4.2 0.46 97.48 23 92.39 
No significance changes are observed after stability study. 
 
%Drug Release in Graphical Presentation 
 
Figure 14: Stability Studies batch In Vitro %Drug 
Release 
CONCLUSION 
Many patients are suffering from the gastro-esophageal 
reflux disease and this can be overcome by using raft 
forming floating tablet of Ondansetron hydrochloride. It 
was concluded that raft forming floating tablet 
containing HPMC K 200M, HPMC K 4M, sodium 
alginate and sodium bicarbonate form raft on 0.1N HCL 
which form suffering raft strength to prevent reflux of 
the gastric content. 
The data obtained thus suggests that gastroretentive drug 
delivery system can be successfully designed to give 
controlled drug delivery, improve bioavailability and 
other desirable characteristics.  
The present study shows that Ondansetron HCl can are 
made into floating Dosage form and raft forming by 
direct compression technique. Floating tablet of 
Ondansetron HCl is shorter lag time. 
Ondansetron HCl floating tablet were prepared by direct 
compression technique and found to be good with 
chipping, capping, and sticking. 
FIR and DSC study indicates no drug-excipient 
interaction in the formulation. 
The in-vitro dissolution profile of optimized floating 
tablet formulated of Ondansetron HCl were found 
sustained drug release up to 12 hours and release can be 
extended for longer period over 12 hours by increasing 
the concentration of polymers. 
3
2 
full factional design and optimization technique 
successfully used in the development of floating tablet. 
Comparing the all formulations, formulation A3 was 
considered as optimized formulation which exhibited 
97.48% of drug release in 12 hours, and floating lag time 
of 30 sec, total floating over 12 hours. 
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